What was the main objective of the IM-UNITI maintenance study?

A. To investigate the efficacy and safety of Ustekinumab 90 mg q8w or q12w versus placebo over a 44-week period

B. To investigate the efficacy and safety of Ustekinumab 130 mg q5w or q10w versus placebo over a 44-week period

C. To investigate the efficacy and safety of Ustekinumab 80 mg q12w versus adalimumab or placebo over a 44-week period

D. To investigate the efficacy and safety of Ustekinumab ~6 mg/kg or 130 mg versus placebo over a 48-week period